LEXINGTON, Mass., March 29 /PRNewswire/ -- ActivBiotics, Inc., a private biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterials and anti-inflammatory agents for inflammatory and infectious disease markets, announced today that David J. McLachlan has been appointed to serve on the Board to replace Richard U. De Schutter.
David J. McLachlan was the Executive Vice President and Chief Financial Officer of Genzyme Corporation from 1989 to 1999 and a senior advisor to Genzyme's chairman and chief executive officer through June 2004. Currently he serves as a Director of Dyax Corp., a biotechnology company, HearUSA, a hearing care company and Skyworks Solutions, Inc., a manufacturer of analog, mixed signal and digital semiconductors for mobile communications. He is also a Director of BioProcessors Corp., a biopharmaceutical equipment manufacturer and Peptimmune, Inc., a biotechnology company. He is a graduate of Harvard Business School and Harvard College.
"David brings seasoned experience, particularly in the financial arena, which will be important as the company plans for its transition to the public markets in the near future," stated Alan W. Dunton, M.D., Chairman of the ActivBiotics Board of Directors.
Mr. De Schutter, who served as Chairman of Metaphore, Inc. prior to the recent merger with ActivBiotics said, "While my other commitments preclude me playing an active role in ActivBiotics, I am confident in the leadership in the Company, especially given the addition of David to the Board."
About ActivBiotics
ActivBiotics, Inc., located in Lexington, MA is a private biopharmaceutical company focused on the discovery, development and commercialization of breakthrough antibacterials for high-value chronic and infectious disease markets. The Company's lead product candidate, rifalazil, is undergoing clinical development trials in multiple indications. The Company's lead pre-clinical compound in a pipeline of novel rifamycins, ABI-0043, shows significant potential for the treatment of infections caused by Gram-positive pathogens, including Chlamydia pneumoniae, Staphylococcus aureus and MRSA (methicillin-resistant Staphylococcus aureus).
Through its wholly owned subsidiary, Metaphore Pharmaceuticals, the Company is also developing a small molecule compound, as well as the class, that mimic the functions of superoxide dismutase, a beneficial human enzyme. The compound M40403 has been studied in Phase 1 and Phase 2 trials in 680 patients and subjects. Current product development efforts are focused on inflammation and diseases related to oxygen free radical toxicity.
For more information on ActivBiotics, please visit our web site at: http://www.activbiotics.com.
ActivBiotics, Inc.CONTACT: Mr. Glenn Kazo, Chief Business Officer of ActivBiotics, Inc.,+1-781-372-4864, gkazo@activbiotics.com
Web site: http://www.activbiotics.com/
